KOL Event tonight 10 Sept (by webcast), page-22

Thanks Roka - Hardman research is paid for by BNO - so treat with care ie don't necessarily believe every number or comment!

As an aside, I have had another thought about why PTSD results announcement seems to have been slower that what I'd have expected......

The company may have asked the clinical trial contractor to hang onto the results while they try and licence BNC 210 ahead of them getting holf of the results because once in posession yhey are obliged to inform the market.

So if they are working on a desl thrn asking the clinicsl trial contractor to hold onto the results temporarily is a no brainer.

This sort of makes sense if they can get a good enough offer for BNC 210 - in the unlikelihood event of bad results. One would assume Merck to be the most likely "partner" (again).

However, given the share price, market cap and greatly diminished net cash position. Merck is probably not wanting to pay up now at the risk of getting a disappointing readout.

That woild be a career limiting decision that few executives would want to make I suspect.

So its all pretty opaque - as is the failure to sell oncology assest by now - both frustrating and disappointing.

Rather than licencing BNC 210 it may be cheaper for Merck to buy the whole company - now wouldn't that be a funny end to this shaggy dog story!!!!

I wonder what they would pay for the whole kit and kaboodle???? No rufus, not a labradoodle!

Food for thought or just wishful thinking - you tell me!